See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

GeoVax Revises Gedeptin® Clinical Strategy Following KEYNOTE-689 Trial Results

Summary by Evertise
GeoVax Labs, Inc. has announced a significant update to its Gedeptin® clinical development program, shifting focus towards evaluating Gedeptin as a neoadjuvant therapy in combination with pembrolizumab for patients with primary, resectable head and neck squamous cell carcinoma (HNSCC). This strategic revision is a direct response to the promising results of the KEYNOTE-689 Phase 3 trial, which showcased a notable improvement in event-free surviv…
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

3 Articles

channelchek.comchannelchek.com

Release - GeoVax to Advance Gedeptin(R) into First-Line Therapy Neoadjuvant Combination Trial Following Landmark KEYNOTE-689 Results - Channelchek

Open the article to view the coverage from channelchek.com

Read Full Article
EvertiseEvertise

GeoVax Revises Gedeptin® Clinical Strategy Following KEYNOTE-689 Trial Results

GeoVax Labs, Inc. has announced a significant update to its Gedeptin® clinical development program, shifting focus towards evaluating Gedeptin as a neoadjuvant therapy in combination with pembrolizumab for patients with primary, resectable head and neck squamous cell carcinoma (HNSCC). This strategic revision is a direct response to the promising results of the KEYNOTE-689 Phase 3 trial, which showcased a notable improvement in event-free surviv…

Read Full Article
NewMediaWireNewMediaWire

GeoVax to Advance Gedeptin® Into First-Line Therapy Neoadjuvant Combination Trial Following Landmark KEYNOTE-689 Results

Open the article to view the coverage from NewMediaWire

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

NewMediaWire broke the news in on Thursday, July 24, 2025.
Sources are mostly out of (0)

Similar News Topics

You have read 1 out of your 5 free daily articles.

Join millions of well-informed readers who use Ground to compare coverage, check their news blindspots, and challenge their worldview.

News
For You
SearchBlindspotLocal